Programmed Cell Death of Endothelial Cells in Ischemic Heart Disease: Mechanism and Potential Cell and Gene Therapeutic Prospects.

Zijia Sun, Lei Chen, Yingying Cao, Bingyang Dai, Lintao Wang, Ling Zhang

Abstract readReview

In one paragraph

Review in Bioengineering (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Zijia SunDepartment of Rehabilitation, Children's Hospital of Nanjing Medical University, Nanjing 210003, China.ORCID 0009-0002-7405-379X

Lei ChenDepartment of Cardiology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou 221002, China.

Yingying CaoZhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou 310022, China.

Bingyang DaiDepartment of Biomedical Engineering, Faculty of Engineering, The Hong Kong Polytechnic University, Hong Kong SAR, China.ORCID 0000-0002-6193-8516

Lintao WangDepartment of Cardiology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing 210003, China.ORCID 0000-0003-2794-7387

Ling ZhangDepartment of Rehabilitation, Children's Hospital of Nanjing Medical University, Nanjing 210003, China.

Funding

Medical Science and Technology development Foundation, Nanjing Department of Health YKK24067Medical Science and Technology Program of Zhejiang Province 2025KY702National Natural Science Foundation of China 82202700Start-up Fund for RAPs under the Strategic Hiring Scheme funded by Hong Kong Polytechnic University P0051062,Start-up Fund for RAPs under the Strategic Hiring Scheme funded by Hong Kong Polytechnic University UGC, P0058838

6 · The paper itself

Abstract

Ischemic heart disease (IHD) is the leading cause of death worldwide, accounting for over eight million deaths each year. IHD encompasses a spectrum of conditions, including atherosclerosis (AS), myocardial infarction (MI), and ischemia/reperfusion (I/R) injury. Programmed cell death (PCD) of endothelial cells (ECs) plays a critical role in IHD pathogenesis, causing microvascular dysfunction, barrier disruption and exacerbation of cardiac injury. PCD involves different signaling pathways, but they are interconnected. Therefore, it is crucial to understand the mechanisms underlying the various forms of PCD in ECs to develop therapeutic strategies for IHD. This review focuses on the molecular mechanisms of PCD of ECs in IHD and provides comprehensive summary of potential cell and gene therapy therapeutic strategies for the treatment of IHD.

Indexed as

cell therapyendothelial cellsgene therapyischemic heart diseaseprogrammed cell death

Identifiers

PMID42351906

DOI10.3390/bioengineering13060661

PMCPMC13295789

What Socratic holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.